Shares of Midatech Pharma plc (NASDAQ:MTP – Get Rating) passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $2.14 and traded as low as $1.50. Midatech Pharma shares last traded at $1.51, with a volume of 7,029 shares traded.
Midatech Pharma Price Performance
The company has a 50-day simple moving average of $2.14 and a two-hundred day simple moving average of $2.83.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Midatech Pharma stock. Great Valley Advisor Group Inc. acquired a new position in Midatech Pharma plc (NASDAQ:MTP – Get Rating) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 49,600 shares of the company’s stock, valued at approximately $27,000. Great Valley Advisor Group Inc. owned about 0.25% of Midatech Pharma at the end of the most recent quarter. Hedge funds and other institutional investors own 3.37% of the company’s stock.
Midatech Pharma Company Profile
Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection.
- Get a free copy of the StockNews.com research report on Midatech Pharma (MTP)
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML’s November Rally Have Staying Power?
- Is Advance Auto Parts a Buy After its Earnings Crash?
- BJ’s Wholesale Club: Beware The Sell-Side
- The Next Catalyst For Mullen Automotive Stock Is December 23rd
Receive News & Ratings for Midatech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.